Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.								
	Substitute for	form 1449/					Complete if Known	
	INFORMATIO	SURE		Application Number		10/771,833		
	STATEMENT	BY APPLI	CANT	NOV 2 O 70	Filing	Date .	02/03/2004	
			13	. = 0 20	Figst	Named Inventor	Dean R. Artis	
			10	3	ABY Ur	it	1656	
	(use as many sh	eets as ne	cessar	Xes	Z xam	ner Name	Kim, Alexander D.	
Sheet	1	of	7		Attorn	ey Docket Number	039363-1106	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	A1	2001/0008765	07-19-2001	Shinoki et al.				
	A2	2001/0012537	08-09-2001	Anderson et al.				
	А3	2001/0014448	08-16-2001	Chappa et al.				
	A4	2001/0014449	08-16-2001	Nerenberg et al.				
	A5	2001/0016322	08-23-2001	Caren et al.				
	A6	2001/0018642	08-30-2001	Balaban et al.				
	A7	2001/0019827	09-06-2001	Dawson et al.				
	A8	2001/0039271	11-08-2001	Bunnage et al.				
	A9	2002/0009764	01-24-2002	Thompson et al.				
	A10	2002/0058606	05-16-2002	Gonzalez et al.				
	A11	2002/0065286	05-30-2002	Davies et al.				
	A12	2002/0091129	07-11-2002	Booleli				
	A13	2002/0128171	09-12-2002	Watkins et al.				
	A14	2002/0165237	11-07-2002	Fryburg et al.				
	A15	2002/0168424	11-14-2002	Shahinpoor et al.				
	A16	2002/0173502	11-21-2002	Allerton				
	A17	2004/0171062	09-02-2004	Hirth et al.				
	A18	4150949	04-24-1979	Smith				
	A19	5698401	12-16-1997	Fesik et al.				
	A20	5804390 .	09-08-1998	Fesik et al.				
	A21	5840485	11-24-1998	Lebl et al.				
	A22	6090912	07-18-2000	Lebl et al.				
	A23	6100254	08-08-2000	Budde et al.				
	A24	6130053	10-10-2000	Thompson et al.				
	A25	6197495	03-06-2001	Qiu et al.				
	A26	6288234	09-11-2001	Griffin				
•	A27	6297021	10-02-2001	Nienaber et al.				
	A28	6465494	10-15-2002	Earle et al.				
	A29	6479493	11-12-2002	Whitehead et al.				

	UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS							
Examiner Initials*	Cite No.1	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
				•				

Examiner Date Considered	
	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute	for form 1449/	PTO	Complete if Known			
	INFORMATI	ON DISCLO	SURE	Application Number	10/771,833		
	STATEMEN	T BY APPLI	CANT	Filing Date	02/03/2004		
				First Named Inventor	Dean R. Artis		
				Art Unit	1656		
	(use as many	sheets as ne	cessary)	Examiner Name	Kim, Alexander D.		
Sheet	2	of	7 .	Attorney Docket Number	039363-1106		

Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	 -
	A30	WO 99/63931	12-16-1999	The Salk Institute for Biological Studies		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Тв
	A31	ASHANI and Wilson, A covalent affinity column for the purification of acetylcholinesterase. Biochem. Biophys. Acta, 276:317-322, 1972.	
	A32	BASHFORD et al., (1987) Spectrophotometry and Spectrofluorometry: A Practical Approach, pp. 91-114, IRL Press Ltd	
	A33	BOGER et al., Synthesis of a functionalized rigid bicycle[2,2,1]heptane: a useful hapten for eliciting catalytic antibodies. Journal of Organic Chemistry, 59:5078-5079, 1994.	
ı.	A34	BOLGER, "Molecular Biology of the Cyclic AMP-Specific Cyclic Nucleotide Phosphodiesterases: A Diverse Family of Regulatory Enzymes," <i>Cellular Signaling</i> 6(8):851-859 (1994)	
	A35	BOS et al., The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology, 9:165-169, 2000.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

•	Substitute	for form 1449/	PTO ·	Complete if Known			
	INFORMATI	ON DISCLO	SURE	Application Number	10/771,833		
	STATEMEN	T BY APPL	ICANT	Filing Date	02/03/2004		
				First Named Inventor	Dean R. Artis		
				Art Unit	1656		
	(use as many	sheets as ne	ecessary)	Examiner Name	Kim, Alexander D.		
Sheet	3	of	7	Attorney Docket Number	039363-1106		

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	publisher, city and/or country where published.						
	A36	BURGERS et al, "Stereochemistry of hydrolysis of adenosine 3':5'-cyclic phosphorothioate by the cyclic phosphodiesterase from beef heart." The Journal of Biological Chemistry, 254 (20): 9959-9961 (1979)						
	A37	BUTCHER and SUTHERLAND, "Adenosine 3',5'-Phosphate in biological materials." The Journal of Biological Chemistry, 237 (4): 1244-1250 (1962)						
	A38	TAYLOR, et al., "The Rapid Generation of Oligonucleotide-Directed Mutations at High Frequency Using Phosphorothioate-Modified DNA," Nucleic Acids Research 13:8765-8785 (1985)						
	A39	FEINBERG et al., Zinc-directed inhibitors for zinc proteinases. Acta Cryst., D51: 428-449, 1995.						
	A40	FELDER, E.R., "The Challenge of Preparing and Testing Combinatorial Compound Libraries in the Fast Lane, at the Front End of Drug Development," <i>Chimia</i> 48:531-541 (1994)						
	A41	FISHER, et al., Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase, <i>J. Biol. Chem.</i> , 273:15559-15564 (1998).						
	A42	FITZGERALD et al., Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. The Journal of Biological Chemistry, 265 (24): 14209-14219, 1990.						
	A43	GELLER et al., HIV-1 protease and its inhibitors in Theoretical and Computational Mthods in Genome Research. Edited by Sahai. New York: Plenum Press, 1997, p. 237-254.						

	يسحب ببرند عبس	
Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

	Substitute f	or form 1449/	PTO	Complete if Known			
	INFORMATI	ON DISCLO	SURE .	Application Number	10/771,833		
	STATEMEN	T BY APPL	ICANT	Filing Date	02/03/2004		
				First Named Inventor	Dean R. Artis		
				Art Unit	1656	·	
	(use as many s	heets as ne	cessary)	Examiner Name	Kim, Alexander D.		
Sheet	4	of	7	Attorney Docket Number	039363-1106		

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1							
	A44	GILLILAND et al., Crystallization of biological macromolecules for X-ray diffraction studies. Current Opinion in Structural Biology, 6:595-603 (1996).						
	A45	GOLDBERG, et al., "O-Labeling of Guanosine Monophosphate Upon Hydrolysis of Cyclic Guanosine 3':5'-Monophosphate by Phosphodiesterase," <i>Journ. Of Biol. Chem.</i> 255:10344-10347 (1980)						
	A46	JIN, et al., "Characterization of the Structure of a Low K _m , Rolipram-sensitive cAMP Phosphodiesterase," Journ. of Biol. Chem. 267:18929-18939 (1992)						
	A47	KEISS et al., Beta-Galactosidase decreases the binding affinity of the insulin-like-growth-factor-ii/mannose-6-phosphate receptor for the insulin-like-growth-factor II. European Journal of Biochemistry, 190:71-77, 1990						
:	A48	KLEINBERG and Wanke, New approaches and technologies in drug design and discovery. Am. J. Health-Syst Pharm., 52: 1323-1336, 1995.						
	A49	MANGANIELLO et al., Cyclic nucleotide phosphodiesterases: Structure, regulation and drug action, Beavo and Houslay, editors, New York: John Wiley & Sons, Inc., 1990, p. 61-85.	ļ					
	A50	MARYANOFF et al., Structure activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. Journal of Medicinal Chemistry, 41:1315-1343, 1998.						
	A51	MCPHERSON et al., The Role of X-ray crystallography in structure-based rational drug designs. Chapter 6 in Chemical Structures Approaches Ration. Drug Design. Edited by D.V. Weiner et al. Boca Raton: CRC Press, 1995, p. 161-179.						

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute	for form 1449/	PTO	Complete if Known		
	INFORMATI	ON DISCLO	SURE	Application Number	10/771,833	
	STATEMEN	T BY APPL	CANT	Filing Date	02/03/2004	
				First Named Inventor	Dean R. Artis	
				Art Unit	1656	
	(use as many s	sheets as ne	cessary)	Examiner Name	Kim, Alexander D.	
Sheet	5	of	7	Attorney Docket Number	039363-1106	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶			
	A52	MICHAELI, et al., "Isolation and Characterization of a Previously Undetected Human cAMP Phosphodiesterase by Complementation of cAMP Phosphodiesterase-deficient Saccharomyces cerevisiae," Journ. of Biol. Chem. 268:12925-12932 (1993)				
	A53	PHAN et al., Extensively methylated myosin subfragment-1; Examination of local structure, interactions with nucleotides and actin, and ligand-induced conformational changes. Biochemistry, 33:11286-11295, 1994.				
	A54	RALL and SUTHERLAND, "Formation of a Cyclic Adenine Ribonucleotide by Tissue Particles," Dept. of Pharmacology, School of Medicine 1065-1076 (1957)				
	A55	ROSENBERRY et al., Purification of acetylcholinesterase by affinity chromatography and determination of active site stoichiometry. The Journal of Biological Chemistry, 247 (5): 1555-15565, 1972.				
	A56	SICA et al., Affinity chromatography and the purification of estrogen receptors. The Journal of Biological Chemistry, 248 (18): 6543-6558, 1973.				
	A57	SODERLING, et al., "Cloning and Characterization of a cAMP-Specific Cyclic Nucleotide Phosphodiesterase," <i>Proc. Natl. Acad. Sci. USA</i> 95:8991-8996 (1998)				
	A58	SODERLING, et al., "Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases," <i>Journ. Biol. Chem.</i> 273(25):15553-15558 (1998)				

	P-10-10-10-10-10-10-10-10-10-10-10-10-10-	
Examiner Signature	Date Considered	
		The state of the s

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control

number.

	Substitute	for form 1449/I	PTO		Complete if Known	
	INFORMAT	ION DISCLO	SURE	Application Number	10/771,833	
	STATEMEN	IT BY APPLI	CANT	Filing Date	02/03/2004	
				First Named Inventor	Dean R. Artis	
				Art Unit	1656	
(use as many sheets as necessary)				Examiner Name	Kim, Alexander D.	
Sheet	6	of	7	Attorney Docket Number	039363-1106	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	No.1 No.1 No.1 No.1 No.1 No.1 No.1 No.1				
	A59	SONNENBURG, et al., "Identification of Inhibitory and Calmodulin-binding Domains of the PDE1A1 and PDE1A2 Calmodulin-stimulated Cyclic Nucleotide Phosphodiesterases," Journ. of Biol. Chem. 270:30989-31000 (1995)			
	A60	THOMPSON, et al., "Regulatory Mechanisms of Particulate Cyclic Nucleotide Phosphodiesterases," Adv. In Sec. Mess. and Phosph. Res. 25:165-184 (1992)			
	A61	UNDERWOOD, et al., "Comparison of Phosphodiesterase III, IV and Dual III/IV Inhibitors on Bronchospasm and Pulmonary Eosinophil Influx in Guinea Pigs," <i>Journ. of Pharm. and Exp. Ther.</i> 270(1):250-259 (1994)			
	A62	WIENCEK, New strategies for protein crystallization growth. Ann.Rev.Biomed.Eng., 1:505-534, (1999).			
	A63	WUTHRICH, K., "Three Dimensional Protein Structures by NMR," Library of Congress 176-199 (1986)			
	A64	WUTHRICH, NMR-This other method for protein and nucleic acid structure determination. Acta Cryst., D51: 249-270, 1995.			
	A65	YAMAZAKI, et al., "Cyclic GMP-specific, High Affinity, Noncatalytic Binding Sites on Light-activated Phosphodiesterase," Journ. of Biol. Chem. 255(23):11619-11624 (1980)			
	A66	YANG ET AL., Peptide analogs from E-cadherin with different calcium-binding affinities. Journal of Peptide Research, 55:203-215, 2000.			

Examiner Signature	Date Considered

This collection of Information Is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute	for form 1449/	PTO	Complete if Known			
	INFORMAT	ION DISCLO	SURE	Application Number	10/771,833		
	STATEMEN	IT BY APPLI	CANT	Filing Date	02/03/2004		
•				First Named Inventor	Dean R. Artis		
				Art Unit	1656		
	(use as many	sheets as ne	cessary)	Examiner Name	Kim, Alexander D.		
Sheet	7	of	7	Attorney Docket Number	039363-1106		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T6
	A67	HAFNER et al., Biotechniques 2001 Apr;30(4):852-6, 858, 860 passim.	

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

AVIG 17 2006 QUnder the Papers U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE k Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

yumber. TRADE Substitute for form 1449B/PTO Complete if Known 10/771.833 INFORMATION DISCLOSURE **Application Number** STATEMENT BY APPLICANT 2/3/2004 Filing Date First Named Inventor Dean R. Artis **Group Art Unit** 1656 (use as many sheets as necessary) **Examiner Name** Kim, Alexander D. Sheet 1 of 2 **Attorney Docket Number** 039363-1106

U.S. PATENT DOCUMENTS									
_		U.S. Patent	Document		Date of Publication of	Pages, Columns, Lines, Where Relevant			
Examiner Initials*	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear			
									

		UNPUBLISH	HED U.S. PATENT APPLICATION	DOCUMENTS	
Cite No.1	U.S. Patent Application Document		Name of Detector or Applicant of	Filing Date of	Pages, Columns, Lines, Where Relevant
	Serial Number	Kind Code ² (if known)	Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
		Cite Docume	Cite No.1 Serial Number Code ² (if	Cite No.1 Serial Number Code ² (ii Name of Patentee or Applicant of Cited Document	Cite Document Name of Patentee or Applicant of Cited Document MM-DD-YYYY

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Fore Office 3	eign Patent D Number ⁴	Oocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T.º

		NON PATENT LITERATURE DOCUMENTS				
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(spublisher, city and/or country where published.				
AK	A1	DYM et al., Molecular docking of competitive phosphodiesterase inhibitors, Molecular Pharmacology, 61:20-25, 2002				
	A2	HADDAD et al., Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (Interleukin-6 and tumor necrosis factor-α) Biosynthesis in alveolar epithelial cells, The Journal of Pharmacology and Experimental Therapeutics, 300:559-566, 2002				
	A3 ·	HUAI et al., Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity, Structure, 11:865-873, 2003				
	A4	MANNING et al., Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B, British Journal of Pharmacology, 128:1393-1398, 1999				

Date Considered	2/8/2001
	1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Sübstitute fo	or form 1449E	3/PTO	Complete if Known		
	INFORMATI	ON DISCLO	DSURE	Application Number	10/771,833	
STATEMENT BY APPLICANT				Filing Date	2/3/2004	-
				First Named Inventor	Dean R. Artis	
				Group Art Unit	1656	
(use as many sheets as necessary)			ecessary)	Examiner Name	Kim, Alexander D.	
Sheet	2	of	2	Attorney Docket Number	039363-1106	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T®		
AK	A5 .	TEJADA et al., The phosphodiesterase inhibitory selectivity and the <i>in vitro</i> and <i>in vivo</i> potency of the new PDE5 inhibitor vardenafil, International Journal of Impotence Research, 13:282-290, 2001			

Examiner Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.